Palbociclib Pharmacokinetics Study In Postmenopausal Chinese Women With ER (+), HER2 (-) Advanced Breast Cancer
Status:
Unknown status
Trial end date:
2020-01-26
Target enrollment:
Participant gender:
Summary
As part of the global clinical development program for Palbociclib, studies are planned in
cancer patients in China. An assessment of Palbociclib pharmacokinetics in Chinese patients,
as required by the Chinese Health Authorities, is therefore warranted. In addition, safety
and efficacy will be also evaluated.
The single and multiple 125 mg oral dose pharmacokinetics of Palbociclib will be
characterized.